Investigating new treatments for Alzheimer's disease using small molecules to target a specific enzyme.
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
This study is exploring a new way to help people with Alzheimer's by targeting a specific enzyme in the brain that produces harmful substances, with the hope that a new treatment could make a positive difference for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-10991314 on NIH RePORTER |
What this research studies
This research focuses on developing innovative treatments for Alzheimer's disease by targeting the tryptophan 2,3-dioxygenase (TDO) enzyme, which is involved in the production of neurotoxic metabolites that may contribute to the disease. The approach involves using small molecules to destabilize a non-catalytic binding site on the TDO enzyme, potentially reducing the harmful effects of these metabolites in the brain. By regulating the biosynthesis of these neurotoxins, the research aims to provide a new therapeutic strategy for patients suffering from Alzheimer's disease. Patients may benefit from this research if the new treatment proves effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing neurodegenerative conditions.
Not a fit: Patients with neurodegenerative diseases other than Alzheimer's or those with non-neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that addresses the underlying causes of Alzheimer's disease rather than just alleviating symptoms.
How similar studies have performed: While targeting the kynurenine pathway is a relatively novel approach, preliminary studies have shown promise in similar strategies for neurodegenerative diseases.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Trombley, Trevor — Purdue University
- Study coordinator: Trombley, Trevor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.